Upsher-Smith: UpsherSmith launches Torpenz tablets to treat tuberous sclerosis complex
Upsher─Smith Laboratories, LLC (Upsher─Smith) announced the recent launch of Torpenz (everolimus) tablets in 2.5 mg, 5 mg, 7.5 mg and 10 mg strengths. Torpenz is an oral mTOR inhibitor used in patients with tuberous sclerosis complex (TSC).
Read full article »
Chairman & CEO
Taku Nakaoka
Upsher-Smith is a Minnesota-based pharmaceutical company that develops and commercializes generic drugs for the treatment of migraines and seizure disorders.
Read more